Human medicines European public assessment report (EPAR): Bosulif, bosutinib, Date of authorisation: 27/03/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Abilify, aripiprazole, Date of authorisation: 04/06/2004, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Date of refusal: 25/04/2013, Revision: 36, Status: Authorised

Substance and product data management services

IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants

Human medicines European public assessment report (EPAR): Usymro, ustekinumab, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Tolvaptan Accord, tolvaptan, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Onureg, azacitidine, Date of authorisation: 17/06/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 26, Status: Authorised